Targeting SIRPα with BMS-986351 led to potent inhibition of SIRPα-CD47 binding and increased phagocytic activity in in vitro models of colorectal cancer, SCCHN, and DLBCL cell lines. This evidence concerns the gene SIRPA and diffuse large B-cell lymphoma.